Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$10.51 +0.3%	$20.41	$48.48 ▼ $105.00	$304.63M	0.95	13,616 shs	271,204 shs
GLUE Monte Rosa Therapeutics	$4.66 -2.3%	$4.51	$3.21 ▼ $12.40	$293.40M	1.4	1.08 million shs	317,903 shs
PYXS Pyxis Oncology	$1.18 -7.8%	$1.18	$0.83 ▼ $5.39	$79.29M	1.18	737,765 shs	509,268 shs
RCKT Rocket Pharmaceuticals	$2.59 -2.3%	$5.02	$2.19 ▼ $26.98	$282.98M	0.68	2.15 million shs	3.23 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+0.29%	+11.69%	+49.50%	-88.13%	-79.15%
GLUE Monte Rosa Therapeutics	-2.31%	+3.79%	+16.79%	-8.63%	+26.29%
PYXS Pyxis Oncology	-7.81%	+3.51%	-4.84%	+11.32%	-63.24%
RCKT Rocket Pharmaceuticals	-2.26%	-8.48%	+11.16%	-65.88%	-87.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	2.0653 of 5 stars	3.4	1.0	0.0	0.0	2.7	1.7	0.6
PYXS Pyxis Oncology	1.9023 of 5 stars	3.4	2.0	0.0	0.0	2.0	0.8	0.6
RCKT Rocket Pharmaceuticals	4.9541 of 5 stars	4.2	4.0	0.0	4.7	2.8	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	232.62% Upside
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	662.71% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	618.15% Upside

Current Analyst Ratings Breakdown

Latest PYXS, RCKT, AVTE, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
GLUE Monte Rosa Therapeutics	$75.62M	3.79	N/A	N/A	$3.63 per share	1.28
PYXS Pyxis Oncology	$16.15M	4.53	N/A	N/A	$2.03 per share	0.58
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	58.26	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)
PYXS Pyxis Oncology	-$77.33M	-$1.59	N/A	N/A	N/A	N/A	-57.49%	-45.17%	8/13/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest PYXS, RCKT, AVTE, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest PYXS, RCKT, AVTE, and GLUE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61
PYXS Pyxis Oncology	N/A	7.75	7.75
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
GLUE Monte Rosa Therapeutics	79.96%
PYXS Pyxis Oncology	39.09%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
GLUE Monte Rosa Therapeutics	6.90%
PYXS Pyxis Oncology	10.60%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.27 million	Optionable
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

PYXS, RCKT, AVTE, and GLUE Headlines

Recent News About These Companies

RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

5 hours ago | prnewswire.com

Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion

June 26 at 5:44 PM | globenewswire.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join – Contact The Gross Law Firm

June 26 at 4:45 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 26 at 4:00 PM | globenewswire.com

Deadline Approaching: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

June 26 at 2:01 PM | businesswire.com

Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) should contact The Gross Law Firm about pending Class Action - RCKT

June 26 at 9:00 AM | prnewswire.com

Bet365 bonus code NYPBET: Claim $150 bonus or $1K first bet safety net for the Rocket Classic

June 26 at 8:06 AM | nypost.comN

Rocket Classic livestream: Where to watch golf tournament round 1, TV, schedule

June 26 at 8:06 AM | msn.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders

June 25 at 9:52 PM | theglobeandmail.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

June 25 at 8:12 PM | globenewswire.com

INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Robbins Geller

June 25 at 11:45 AM | globenewswire.com

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

June 25 at 11:29 AM | globenewswire.com

Rocket Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKT - Morningstar

June 25 at 2:06 AM | morningstar.comM

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

June 24 at 4:18 PM | globenewswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors To Inquire About Securities Fraud Class Action

June 24 at 1:13 PM | businesswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

June 24 at 11:29 AM | globenewswire.com

Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RCKT

June 24 at 9:00 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKT

June 23, 2025 | globenewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

June 23, 2025 | globenewswire.com

Law Offices of Frank R. Cruz Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors To Inquire About Securities Fraud Class Action

June 23, 2025 | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Hold" from Brokerages

June 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, RCKT, AVTE, and GLUE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$10.51 +0.03 (+0.29%)

As of 06/25/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.66 -0.11 (-2.31%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.66 0.00 (0.00%)

As of 06/26/2025 06:55 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Pyxis Oncology NASDAQ:PYXS

$1.18 -0.10 (-7.81%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.20 +0.02 (+1.61%)

As of 06/26/2025 07:16 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.59 -0.06 (-2.26%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.58 0.00 (-0.19%)

As of 06/26/2025 07:58 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time